AI Engines For more Details: Perplexity Kagi Labs You
Myasthenia Gravis Treatment: Pyridostigmine iodide is a cholinesterase inhibitor that helps improve muscle strength and function in individuals with myasthenia gravis. It works by inhibiting the enzyme acetylcholinesterase, which breaks down the neurotransmitter acetylcholine. By prolonging the action of acetylcholine at the neuromuscular junction, pyridostigmine enhances muscle contraction and improves muscle strength.
Symptom Relief: Pyridostigmine iodide helps alleviate the symptoms of myasthenia gravis, including muscle weakness, fatigue, drooping eyelids (ptosis), double vision (diplopia), difficulty swallowing (dysphagia), and difficulty speaking (dysarthria). It may also improve respiratory function by strengthening the muscles involved in breathing.
Dosage Adjustment: The dosage of pyridostigmine iodide may need to be adjusted based on individual response and tolerance. Healthcare providers typically prescribe an initial low dose, which is gradually increased until optimal symptom control is achieved with minimal side effects.
Maintenance Therapy: Pyridostigmine iodide is often used as a long-term maintenance therapy for myasthenia gravis to manage symptoms and improve quality of life. Regular monitoring by a healthcare professional is necessary to ensure that the medication remains effective and well-tolerated.
Adjunctive Therapy: In some cases, pyridostigmine iodide may be used in combination with other medications, such as corticosteroids, immunosuppressants, or intravenous immunoglobulin (IVIG), to achieve better symptom control in individuals with myasthenia gravis.
Side Effects: Common side effects of pyridostigmine iodide may include gastrointestinal disturbances (such as nausea, vomiting, diarrhea, abdominal cramps), excessive salivation, increased sweating, bradycardia (slow heart rate), muscle twitching, and muscle cramps. These side effects are usually dose-dependent and may diminish over time as the body adjusts to the medication.
Drug Interactions: Pyridostigmine iodide may interact with other medications, including other cholinesterase inhibitors, anticholinergic drugs, and certain antibiotics. These interactions can affect the efficacy and safety of pyridostigmine iodide, leading to potential adverse effects or treatment failure.
Special Populations: Pyridostigmine iodide should be used with caution in individuals with a history of asthma, peptic ulcer disease, bradycardia, or urinary tract obstruction. It should also be used cautiously in pregnant or breastfeeding women, as well as in elderly individuals, who may be more susceptible to its effects.
| Rank | Probiotic | Impact |
|---|
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.2 | 0.2 | |
| ADHD | 0.4 | 0.4 | 0 |
| Age-Related Macular Degeneration and Glaucoma | 0.1 | -0.1 | |
| Allergic Rhinitis (Hay Fever) | 0.1 | 0.1 | |
| Allergies | 0.5 | -0.5 | |
| Allergy to milk products | 0.3 | 0.1 | 2 |
| Alopecia (Hair Loss) | 0.1 | 0.1 | |
| Alzheimer's disease | 0.6 | 1.4 | -1.33 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.4 | 0.2 | 1 |
| Ankylosing spondylitis | 0.4 | 0.3 | 0.33 |
| Anorexia Nervosa | 0.1 | 0.4 | -3 |
| Antiphospholipid syndrome (APS) | 0.3 | 0.2 | 0.5 |
| Asthma | 0.1 | -0.1 | |
| Atherosclerosis | 0.2 | 0.2 | |
| Atrial fibrillation | 1.1 | 0.4 | 1.75 |
| Autism | 1 | 1.5 | -0.5 |
| Barrett esophagus cancer | 0.3 | -0.3 | |
| Bipolar Disorder | 0.6 | 0.6 | 0 |
| Brain Trauma | 0.1 | -0.1 | |
| Carcinoma | 0.9 | 0.4 | 1.25 |
| Celiac Disease | 0.4 | 0.6 | -0.5 |
| Cerebral Palsy | 0.3 | 0.3 | 0 |
| Chronic Fatigue Syndrome | 1.2 | 2.3 | -0.92 |
| Chronic Kidney Disease | 0.1 | 0.6 | -5 |
| Chronic Lyme | 0.1 | -0.1 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.8 | 0.4 | 1 |
| Chronic Urticaria (Hives) | 0.3 | 0.3 | |
| Coagulation / Micro clot triggering bacteria | 0.3 | 0.5 | -0.67 |
| Colorectal Cancer | 0.9 | 0.1 | 8 |
| Constipation | 0.1 | 0.1 | |
| Coronary artery disease | 0.3 | 0.4 | -0.33 |
| COVID-19 | 0.8 | 2.3 | -1.87 |
| Crohn's Disease | 0.9 | 0.9 | 0 |
| cystic fibrosis | 0.1 | -0.1 | |
| deep vein thrombosis | 0.5 | -0.5 | |
| Depression | 0.9 | 2.1 | -1.33 |
| Dermatomyositis | 0.3 | 0.3 | |
| Eczema | 0.8 | -0.8 | |
| Endometriosis | 0.8 | 0.2 | 3 |
| Epilepsy | 0.3 | 0.2 | 0.5 |
| Fibromyalgia | 0.2 | 0.8 | -3 |
| Functional constipation / chronic idiopathic constipation | 0.4 | 0.4 | 0 |
| gallstone disease (gsd) | 0.3 | 0.3 | |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0 | 0.3 | 0 |
| Generalized anxiety disorder | 0.4 | -0.4 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0.4 | -0.4 | |
| Graves' disease | 0.1 | 0.1 | |
| Halitosis | 0.1 | 0.3 | -2 |
| Hashimoto's thyroiditis | 0.1 | 0.3 | -2 |
| Hidradenitis Suppurativa | 0.5 | 0.5 | |
| High Histamine/low DAO | 0.2 | -0.2 | |
| hyperglycemia | 0.1 | -0.1 | |
| hypersomnia | 0.2 | -0.2 | |
| hypertension (High Blood Pressure | 0.6 | 0.9 | -0.5 |
| Hypothyroidism | 0.4 | -0.4 | |
| Hypoxia | 0.1 | 0.1 | |
| IgA nephropathy (IgAN) | 0 | 0 | |
| Inflammatory Bowel Disease | 0.9 | 1.5 | -0.67 |
| Insomnia | 0.3 | 0.1 | 2 |
| Intelligence | 0.4 | 0.4 | |
| Intracranial aneurysms | 0.4 | 0.4 | |
| Irritable Bowel Syndrome | 0.3 | 0.2 | 0.5 |
| Liver Cirrhosis | 1.2 | 1.2 | 0 |
| Long COVID | 1.3 | 1.5 | -0.15 |
| Low bone mineral density | 0.4 | -0.4 | |
| Lung Cancer | 0.2 | -0.2 | |
| Mast Cell Issues / mastitis | 0.3 | 0.6 | -1 |
| ME/CFS with IBS | 0.3 | 0.8 | -1.67 |
| ME/CFS without IBS | 0.4 | 0.2 | 1 |
| Metabolic Syndrome | 1.2 | 1.3 | -0.08 |
| Mood Disorders | 1.7 | 2.1 | -0.24 |
| multiple chemical sensitivity [MCS] | 0.8 | 0.8 | |
| Multiple Sclerosis | 1.4 | 0.9 | 0.56 |
| Multiple system atrophy (MSA) | 0.2 | -0.2 | |
| neuropathic pain | 0.1 | -0.1 | |
| Neuropathy (all types) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.3 | 0.8 | -1.67 |
| NonCeliac Gluten Sensitivity | 0.1 | -0.1 | |
| Obesity | 1.2 | 1.3 | -0.08 |
| obsessive-compulsive disorder | 0.9 | 0.5 | 0.8 |
| Osteoarthritis | 0.3 | 0.2 | 0.5 |
| Osteoporosis | 0.3 | 0.1 | 2 |
| pancreatic cancer | 0.3 | 0.3 | |
| Parkinson's Disease | 1.7 | 1 | 0.7 |
| Polycystic ovary syndrome | 0.4 | 0.5 | -0.25 |
| Postural orthostatic tachycardia syndrome | 0.4 | -0.4 | |
| Premenstrual dysphoric disorder | 0.1 | -0.1 | |
| Psoriasis | 0.5 | 0.6 | -0.2 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.2 | 0.4 | 2 |
| Rosacea | 0.2 | 0.2 | |
| Schizophrenia | 1 | 0.6 | 0.67 |
| scoliosis | 0.4 | 0.5 | -0.25 |
| Sjögren syndrome | 0.3 | 0.2 | 0.5 |
| Sleep Apnea | 0.6 | 0.4 | 0.5 |
| Slow gastric motility / Gastroparesis | 0.3 | 0.3 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.3 | 0.3 | |
| Stress / posttraumatic stress disorder | 0.1 | 0.4 | -3 |
| Systemic Lupus Erythematosus | 1 | 0.2 | 4 |
| Tic Disorder | 0.3 | 0.3 | |
| Tourette syndrome | 0.1 | -0.1 | |
| Type 1 Diabetes | 0.9 | 0.3 | 2 |
| Type 2 Diabetes | 1.3 | 1 | 0.3 |
| Ulcerative colitis | 0.3 | 0.8 | -1.67 |
| Unhealthy Ageing | 1 | 0.5 | 1 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations / Info / Descriptions are influenced by < a href = "/home/sources" target = "_blank" > Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2024 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription
All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.
Inventions / Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [44.222.131 ]
Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [44.222.131 ]
